|
Fichte Biosciences, Inc. (SPRB) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Spruce Biosciences, Inc. (SPRB) Bundle
Möchten Sie den inneren Wert von Fichte Biosciences, Inc. bewerten? Unser (SPRB) DCF-Taschenrechner integriert reale Daten mit umfassenden Anpassungsfunktionen, sodass Sie Projektionen verfeinern und Ihre Anlagestrategien verbessern können.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | 10.1 | 10.1 | 10.1 | 10.1 | 10.1 | 10.1 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -13.1 | -29.1 | -41.6 | -45.3 | -47.4 | 6.1 | 6.1 | 6.1 | 6.1 | 6.1 |
| EBITDA, % | 100 | 100 | 100 | 100 | -469.48 | 60 | 60 | 60 | 60 | 60 |
| Depreciation | .0 | .1 | .4 | .4 | .1 | 8.1 | 8.1 | 8.1 | 8.1 | 8.1 |
| Depreciation, % | 100 | 100 | 100 | 100 | 0.69382 | 80.14 | 80.14 | 80.14 | 80.14 | 80.14 |
| EBIT | -13.1 | -29.2 | -41.9 | -45.8 | -47.4 | 6.1 | 6.1 | 6.1 | 6.1 | 6.1 |
| EBIT, % | 100 | 100 | 100 | 100 | -470.18 | 60 | 60 | 60 | 60 | 60 |
| Total Cash | 3.9 | 157.2 | 89.0 | 79.1 | 96.3 | 10.1 | 10.1 | 10.1 | 10.1 | 10.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | 8.1 | 8.1 | 8.1 | 8.1 | 8.1 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 0 | 80 | 80 | 80 | 80 | 80 |
| Inventories | .0 | .0 | .0 | .0 | .0 | 8.1 | 8.1 | 8.1 | 8.1 | 8.1 |
| Inventories, % | 100 | 100 | 100 | 100 | 0 | 80 | 80 | 80 | 80 | 80 |
| Accounts Payable | 1.9 | 3.6 | 2.8 | 1.4 | 3.3 | 8.7 | 8.7 | 8.7 | 8.7 | 8.7 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 33.03 | 86.61 | 86.61 | 86.61 | 86.61 | 86.61 |
| Capital Expenditure | .0 | -.1 | -.1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | -0.0693825 | -0.0138765 | -0.0138765 | -0.0138765 | -0.0138765 | -0.0138765 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -13.3 | -29.7 | -42.3 | -44.7 | -47.4 | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -11.4 | -27.9 | -42.9 | -45.6 | -45.5 | 3.4 | 14.1 | 14.1 | 14.1 | 14.1 |
| WACC, % | 14.11 | 14.11 | 14.11 | 14.05 | 14.11 | 14.1 | 14.1 | 14.1 | 14.1 | 14.1 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 38.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 14 | |||||||||
| Terminal Value | 119 | |||||||||
| Present Terminal Value | 62 | |||||||||
| Enterprise Value | 100 | |||||||||
| Net Debt | -92 | |||||||||
| Equity Value | 192 | |||||||||
| Diluted Shares Outstanding, MM | 39 | |||||||||
| Equity Value Per Share | 4.99 |
What You Will Get
- Comprehensive SPRB Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust parameters like WACC, tax rates, revenue growth, and capital expenditures.
- Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Explore various scenarios to assess Spruce Biosciences' future prospects.
- User-Friendly Design: Designed for experts but easy to navigate for newcomers.
Key Features
- Comprehensive SPRB Data: Pre-loaded with Spruce Biosciences' historical performance metrics and future growth forecasts.
- Customizable Parameters: Tailor revenue growth, operating margins, discount rates, tax considerations, and capital investments to your needs.
- Interactive Valuation Tool: Real-time adjustments to Net Present Value (NPV) and intrinsic value based on user-defined inputs.
- Multiple Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation possibilities.
- Intuitive User Interface: Designed for ease of use, making it accessible for both industry experts and newcomers.
How It Works
- Step 1: Download the prebuilt Excel template featuring Spruce Biosciences' data.
- Step 2: Navigate through the pre-filled sheets to grasp the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see recalculated results, including Spruce Biosciences' intrinsic value.
- Step 5: Utilize the outputs to make informed investment decisions or create reports.
Why Choose This Calculator for Spruce Biosciences, Inc. (SPRB)?
- Accuracy: Utilizes real Spruce Biosciences financials to ensure precise data.
- Flexibility: Allows users to easily test and adjust inputs as needed.
- Time-Saving: Avoid the complexities of building a financial model from the ground up.
- Professional-Grade: Crafted with the precision and usability expected at the CFO level.
- User-Friendly: Designed for ease of use, suitable for those without extensive financial modeling skills.
Who Should Use This Product?
- Investors: Accurately assess Spruce Biosciences, Inc.'s (SPRB) fair value before making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Spruce Biosciences, Inc. (SPRB).
- Consultants: Efficiently customize the template for valuation reports tailored to Spruce Biosciences, Inc. (SPRB) clients.
- Entrepreneurs: Acquire insights into financial modeling practices utilized by leading biotech firms.
- Educators: Employ it as a teaching resource to illustrate valuation methodologies in the biotech sector.
What the Template Contains
- Pre-Filled DCF Model: Spruce Biosciences' financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Spruce Biosciences' profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.